培美曲赛联合顺铂复治转移性乳腺癌的临床观察

目的观察培美曲赛联合顺铂治疗转移性乳腺癌的疗效及不良反应,为转移性乳腺癌的治疗提供新的思路和方法。方法 8例转移性乳腺癌患者接受培美曲赛联合顺铂方案化疗,培美曲赛500mg/m2,顺铂75mg/m2,静脉滴注,每3周重复1次。每两个疗程评价1次。结果 8例患者均可评价疗效,其中CR2例,PR4例,SD1例,PD1例。中位随访时间为6月（2～22月）。7例存活,1例死亡,中位生存期为10月（2～22个月）。治疗中最常见的不良反应是乏力、白细胞减少和消化道反应以及口腔溃疡。结论培美曲赛联合顺铂方案复治转移性乳腺癌能提高患者生存率,其不良反应可以耐受。

Clinical Observation of the Treatment With Pemetrexed and Cisplatin in the Metastatic Breast Cancer

Objective We observesd the efficacy and adverse reactions of the treatment with pemetrexed and cisplatin in the metastatic breast cancer,in order to provide a new approach.Methods Eight patients with metastatic breast cancer received pemetrexed and cisplatin chemotherapy,the contents of which was pemetrexed 500 mg/m2 intravenous infusion,cisplatin 75 mg/m2 intravenous drip,repeating every 3 weeks.Evaluation of response and adverse reaction were practiced every 2 cycles.Result All of the 8 patients could be evalued.The result was CR 2 patients,PR 4 patients,SD 1 patient,PD 1 patient.The media follow-up was 6 months（2～22 monthes） .Seven patients survived and one patient died.The media survival time was 10 months（2～22 monthes） .The most common adverse reaction was fatigue,white blood cells decrease and the digestive tract reaction,followed by oral ulcers.Conclusion Pemetrexed combined with cisplatin in the treament of metastatic breast cancer could improve survival and the adverse reaction could be tolerated.